792 results on '"Barter, Philip J."'
Search Results
2. High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study)
3. TEMPORARY REMOVAL: Association of elevated circulating fibroblast growth factor 21 levels with prevalent and incident metabolic syndrome: The Multi-Ethnic Study of Atherosclerosis
4. Lipid-Lowering Drugs
5. Visit-to-visit variability of lipid measurements as predictors of cardiovascular events
6. The relationship of circulating fibroblast growth factor 21 levels with incident atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis
7. Relationship of High‐Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin
8. Relationship of fibroblast growth factor 21 levels with inflammation, lipoproteins and non-alcoholic fatty liver disease
9. Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes
10. Relationship of pericardial fat with lipoprotein distribution: The Multi-Ethnic study of atherosclerosis
11. Relationship of pericardial fat with biomarkers of inflammation and hemostasis, and cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis
12. The relationship between insulin resistance and vascular calcification in coronary arteries, and the thoracic and abdominal aorta: The Multi-Ethnic Study of Atherosclerosis
13. Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?
14. Association of elevated circulating fibroblast growth factor 21 levels with prevalent and incident metabolic syndrome: The Multi-Ethnic Study of Atherosclerosis
15. Comparing a novel equation for calculating low-density lipoprotein cholesterol with the Friedewald equation: A VOYAGER analysis
16. CETP inhibition, statins and diabetes
17. Effect of Change in Body Weight on Incident Diabetes Mellitus in Patients With Stable Coronary Artery Disease Treated With Atorvastatin (from the Treating to New Targets Study)
18. Cardiovascular drugs that increase the risk of new-onset diabetes
19. The relationship between total bilirubin levels and total mortality in older adults: the United States National Health and Nutrition Examination Survey (NHANES) 1999-2004.
20. Variations in time to benefit among clinical trials of cholesterol-lowering drugs
21. Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease Risk
22. Transcoronary gradients of HDL-associated MicroRNAs in unstable coronary artery disease
23. Effects of age, gender and statin dose on lipid levels: Results from the VOYAGER meta-analysis database
24. Gaps in beliefs and practice in dyslipidaemia management in Japan, Germany, Colombia and the Philippines: insights from a web-based physician survey
25. Apolipoprotein A-I enhances insulin-dependent and insulin-independent glucose uptake by skeletal muscle
26. The Cholesteryl Ester Transfer Protein Inhibitor, des-Fluoro-Anacetrapib, Prevents Vein Bypass-induced Neointimal Hyperplasia in New Zealand White Rabbits
27. Tumor Necrosis factor-α Induces Adhesion Molecule Expression through the Sphingosine Kinase Pathway
28. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel
29. A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia
30. Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?
31. Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis
32. Apolipoprotein A-I Protects Against Pregnancy-Induced Insulin Resistance in Rats
33. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation
34. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial
35. To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis
36. HDL Structure, Function, and Antiinflammatory Properties
37. HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology
38. Reduction of In-Stent Restenosis by Cholesteryl Ester Transfer Protein Inhibition
39. Abstract 14954: Visit-to-visit Variability of Lipid Measurements as Predictors of Cardiovascular Events
40. In vivo PET imaging with [18F]FDG to explain improved glucose uptake in an apolipoprotein A-I treated mouse model of diabetes
41. Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial
42. High-density lipoproteins: A consensus statement from the National Lipid Association
43. Arthritis: its prevalence, risk factors, and association with cardiovascular diseases in the United States, 1999 to 2008
44. Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study
45. The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study
46. Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis
47. CORONARY ARTERY DISEASE: Scavenger receptor class B1 — a target to reduce CHD risk?
48. Apolipoprotein A-I interactions with insulin secretion and production
49. Evolving Targets of Therapy
50. Contributors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.